Universe Pharmaceuticals Inc
1 hedge funds and large institutions have $1.09K invested in Universe Pharmaceuticals Inc in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
0.52% less ownership
Funds ownership: 0.67% → 0.15% (-0.52%)
67% less funds holding
Funds holding: 3 → 1 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less capital invested
Capital invested by funds: $344K → $1.09K (-$343K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$203K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$141K |
| 3 |
Morgan Stanley
New York
|
-$40 |
UPC Hedge Fund Activity: Q1 2025 in Review
1 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Universe Pharmaceuticals Inc (UPC) for Q1 2025, worth a combined $1.09K — down 100% from $344K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of UPC and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $2.95K. The largest seller was Sabby Management, exiting entirely with an estimated $203K sold.
- 1 institutional investor held Universe Pharmaceuticals Inc (UPC) as of Q1 2025, down from 3 in Q4 2024.
- Funds reported $1.09K of Universe Pharmaceuticals Inc stock for Q1 2025, down 100% quarter-over-quarter.
- 1 fund opened new Universe Pharmaceuticals Inc positions in Q1 2025 and 3 closed out, a net change of -2 holders.
- The largest Universe Pharmaceuticals Inc buyer in Q1 2025 was UBS Group, an estimated $2.95K added.
- The largest Universe Pharmaceuticals Inc seller in Q1 2025 was Sabby Management, an estimated $203K sold.
Based on aggregated 13F filings for Q1 2025.